Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2017 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia

New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 ...
October 26, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

WALTHAM, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...